# OJJAARA (momelotinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/momelotinib

> The FDA approved OJJAARA (momelotinib), sponsored by GSK plc (GSK), on September 15, 2023 for to treat intermediate or high-risk myelofibrosis in adults with anemia.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is OJJAARA (momelotinib) FDA approved?

Yes. The FDA approved OJJAARA (momelotinib), sponsored by GSK plc (GSK), on September 15, 2023 for to treat intermediate or high-risk myelofibrosis in adults with anemia. FDA novel drug approvals: "Ojjaara | momelotinib | 9/15/2023 | To treat intermediate or high-risk myelofibrosis in adults with anemiaDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/momelotinib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/momelotinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | OJJAARA (momelotinib) |
| Codes | GS-0387, CYT387, GSK3070785 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | To treat intermediate or high-risk myelofibrosis in adults with anemia, [Primary Myelofibrosis](https://sec-api.dev/indications/primary-myelofibrosis), [VEXAS Syndrome](https://sec-api.dev/indications/vexas-syndrome), [Myelodysplastic Syndromes](https://sec-api.dev/indications/myelodysplastic-syndromes) |
| Modality | small_molecule |
| FDA designations | orphan |

## Timeline

### September 15, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat intermediate or high-risk myelofibrosis in adults with anemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Ojjaara | momelotinib | 9/15/2023 | To treat intermediate or high-risk myelofibrosis in adults with anemiaDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA216873 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230915, review_priority STANDARD; sponsor_name GLAXOSMITHKLINE; product OJJAARA (MOMELOTINIB DIHYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216873%22

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Primary Myelofibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03441113 (Extended Access of Momelotinib in Adults With Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT03441113

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Primary Myelofibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03441113 (Extended Access of Momelotinib in Adults With Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT03441113

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06517875 (Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06517875

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06517875 (Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-16 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06517875

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06847867 (A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06847867

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Myelodysplastic Syndromes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06847867 (A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06847867

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: VEXAS Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07569081 (A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07569081

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: VEXAS Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07569081 (A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-06 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07569081

## Same indication

- [Arumakimig](https://sec-api.dev/pdufa/arumakimig) (NVS)
- [Decitabine](https://sec-api.dev/pdufa/decitabine) (NVS)
- [Elritercept](https://sec-api.dev/pdufa/elritercept) (TAK)
- [Luspatercept](https://sec-api.dev/pdufa/luspatercept) (BMY)
- [Oral azacitidine](https://sec-api.dev/pdufa/oral-azacitidine) (BMY)
- [Evrenzo® (roxadustat)](https://sec-api.dev/pdufa/roxadustat) (KYNB)
- [Tebapivat](https://sec-api.dev/pdufa/tebapivat) (AGIO)

Calendar months: [December 2026](https://sec-api.dev/fda-calendar/2026-12), [March 2027](https://sec-api.dev/fda-calendar/2027-03), [July 2027](https://sec-api.dev/fda-calendar/2027-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/momelotinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OJJAARA (momelotinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/momelotinib

```bibtex
@misc{secapidev_pdufa_momelotinib_20261116,
  title        = {OJJAARA (momelotinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/momelotinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_momelotinib_20261116","title":"OJJAARA (momelotinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/momelotinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
